PMC:7561592 / 34769-35834 JSONTXT

{"project":"2_test","denotations":[{"id":"33063245-24934549-28146","span":{"begin":1061,"end":1063},"obj":"24934549"}],"text":"Overall, results indicate that when medicines are co-administered with vehicles, the mixtures should be administered as soon as possible after preparation (unless specific data is available). Immediate administration reduces to the potential risk of dosing errors, exposure to light, hydrolysis, oxygen and microbiological contamination, but also minimises other vehicle-effects on drug dissolution (e.g. increased drug solubilisation, potential stability issues). Depending on the formulation, and particularly for enteric-coated dosage forms (case study, Salofalk®), delaying administration of the prepared formulation-vehicle mixture could result in changes in drug dissolution behaviour which might alter drug absorption and, consequently, drug safety and efficacy. Other potential consequences of delaying the administration of the drug-vehicle mixture are an increase of the risk of adverse side effects, depending on the drug category (e.g. for nonsteroidal anti-inflammatory drugs, it might lead to irritation of the GI mucosa and, ultimately, ulcers) (13)."}